Olanzapine in long-term treatment for bipolar disorder
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Many patients with bipolar disorder require long-term treatment to prevent recurrence. Antipsychotic drugs are often used to treat acute manic episodes. It is important to clarify whether olanzapine could have a role in long-term prevention of manic and depressive relapses. OBJECTIVES: To assess the effects of olanzapine, as monotherapy or adjunctive treatment, in preventing manic, depressive and mixed episodes in patients with bipolar affective disorder. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (September 2006), the Cochrane Central Register of Controlled Trials (September 2006), MEDLINE (1966-December 2007), EMBASE (1980-2006), CINAHL (1982-2006), PsycINFO (1872-2006) and reference lists. We also contacted experts, trialists and pharmaceutical companies in the field. SELECTION CRITERIA: Randomised controlled trials comparing olanzapine with placebo or other active treatment in long-term treatment of bipolar disorder. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. MAIN RESULTS: Five trials (1165 participants) were included in the review. There was no statistically significant difference between olanzapine and placebo (either alone or in combination with lithium or valproate) in terms of number of participants who experienced relapse into mood episode (random effects RR 0.68, 95% CI 0.43 to 1.07, p = 0.09; 2 studies, n=460), however restricting the analysis to the trial that compared olanzapine monotherapy versus placebo, there was a statistically significant difference in favour of olanzapine (RR 0.58, 95% CI 0.49 to 0.69, p<0.00001). No statistically significant difference was found between olanzapine and other mood stabilisers (lithium or valproate) in preventing symptomatic relapse for any mood episode, however, olanzapine was more effective than lithium in preventing symptomatic manic relapse (RR 0.59, 95% CI 0.39 to 0.89, p = 0.01; 1 study, n=361). Olanzapine either alone or as adjunctive treatment to mood stabilisers was associated with significantly greater weight gain than placebo. By contrast, olanzapine was associated with a lower rate of manic worsening, but with a higher rate of weight increase and depression than lithium. AUTHORS' CONCLUSIONS: Though based on a limited amount of information, there is evidence that olanzapine may prevent further mood episodes in patients who have responded to olanzapine during an index manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate. However, notwithstanding these positive results, the current evidence is stronger for lithium as first line maintenance treatment of bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Mortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881
Temple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Ellenberg, S. S., & Temple, R. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00015 · Cited by 331
Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317
Nonadherence With Mood Stabilizers: Prevalence and Predictors
Scott, J., & Pope, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0502 · Cited by 315
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
Macritchie, K., Geddes, J., Scott, J., Haslam, D. R., & Goodwin, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003196 · Cited by 263
Self-citation
Cited by
Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., De Herdt, A., Sienaert, P., Probst, M., & De Hert, M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050620 · Cited by 441
Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis
Fountoulakis, K. N., Vieta, E., & Schmidt, F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.018 · Cited by 52
“Recent reviews on maintenance treatment (Beynon et al., 2009; Cipriani et al., 2009; Geddes et al., 2004; Smith et al., 2007a; Young and Newham, 2006) reported that there are data comparing the efficacy of lithium, valproate, lamotrigine, olanzapine, aripiprazole, imipramine and imipramine combined with lithium vs.”
BackgroundThe Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study
Hong, J., Reed, C., Novick, D., Haro, J. M., Windmeijer, F., & Knapp, M. (2010) · PharmacoEconomics · doi:10.2165/11535200-000000000-00000 · Cited by 26
“[6] Despite the disabling nature of BD, few studies have measured the economic impact of the disease in Europe; those that have show that the impact is substantial.”
BackgroundInfluentialPotthast, R., Vervölgyi, V., McGauran, N., Kerekes, M. F., Wieseler, B., & Kaiser, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092067 · Cited by 20
“Cipriani 2009 [25] Recurrence of any affective episode Relapse mania or depression Withdrawals due to AE Withdrawals due to AE Primary outcome”
Background
Metadata
- Authors
- Cipriani, A., Rendell, J. M., & Geddes, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 2010
- Issue
- 1
- Pages
- CD004367-CD004367
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1593754392
- Cited by
- 38
- References
- 9
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olanzapine in long-term treatment for bipolar disorder. https://app.cochat.ai/papers/10.1002/14651858.cd004367.pub2
- The paper
- Cipriani, A., Rendell, J. M., & Geddes, J. (2009). Olanzapine in long-term treatment for bipolar disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004367.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.